Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.43 |
| ▸ | THRB | P10828 | 8/20 | 0.40 |
| ▸ | THRA | P10827 | 3/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9823506 | 0.87 | MEN1 (0.53) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL6490492 | 0.84 | MEN1 (0.56) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL5567160 | 0.84 | MEN1 (0.56) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL9823423 | 0.83 | MEN1 (0.55) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL10394520 | 0.83 | MEN1 (0.53) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL5561466 | 0.81 | MEN1 (0.54) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL5566846 | 0.80 | MEN1 (0.50) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL5561448 | 0.79 | MEN1 (0.55) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL5561444 | 0.79 | MEN1 (0.55) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL9823812 | 0.79 | MEN1 (0.48) | MEN1NR1I2KMT2AP2RX7THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951857-B2 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD | 2005-10-04 | — | — | US | disclosed |
| US-6743792-B2 | ANTIINFLAMMATORY AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-01 | — | — | US | disclosed |
| US-20030220331-A1 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD (BE) | 2003-11-27 | — | — | US | disclosed |
| US-20020042416-A1 | Antiinflammatory agents | FREYNE EDDY JEAN EDGARD (BE) | 2002-04-11 | — | — | US | disclosed |
| EP-1003729-A1 | 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999002504-A1 | 6-AZAURACIL DERIVATIVES AS IL-5 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042416-A1 | Antiinflammatory agents | CCR1, CCR6, FPR1 | MEN1 4743/4885NR1I2 384/4885KMT2A 4147/4885 |
| US-20030220331-A1 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | IL6, CCR1, CCR6 | MEN1 4804/4885NR1I2 624/4885KMT2A 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.